Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $570.58, for a total value of $5,420,510.00. Following the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $23,115,907.54. This trade represents a 19.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

United Therapeutics Price Performance

UTHR stock traded up $10.82 during mid-day trading on Monday, hitting $581.22. 354,866 shares of the stock were exchanged, compared to its average volume of 477,395. The business has a fifty day moving average price of $543.83 and a 200 day moving average price of $498.27. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $607.89. The stock has a market capitalization of $25.47 billion, a price-to-earnings ratio of 20.83, a PEG ratio of 1.62 and a beta of 0.60.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. During the same quarter in the previous year, the company posted $6.19 earnings per share. The company’s revenue was up 7.4% compared to the same quarter last year. As a group, equities analysts forecast that United Therapeutics Corporation will post 27.97 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently commented on UTHR. Bank of America lifted their price objective on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a report on Tuesday, March 31st. Morgan Stanley lifted their price objective on United Therapeutics from $471.00 to $519.00 and gave the stock an “equal weight” rating in a report on Friday, April 10th. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Raymond James Financial began coverage on United Therapeutics in a report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price objective on the stock. Finally, Royal Bank Of Canada lifted their price objective on United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Ten analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $601.50.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of UTHR. Geneos Wealth Management Inc. increased its holdings in United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 85 shares during the period. Northwestern Mutual Wealth Management Co. increased its holdings in United Therapeutics by 18.8% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 70 shares during the period. Jump Financial LLC purchased a new position in United Therapeutics during the 2nd quarter valued at about $277,000. Cerity Partners LLC increased its holdings in United Therapeutics by 77.3% during the 2nd quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock valued at $3,691,000 after purchasing an additional 5,600 shares during the period. Finally, Bank of Nova Scotia increased its holdings in United Therapeutics by 6.9% during the 2nd quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock valued at $468,000 after purchasing an additional 105 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.